NEVRO CORP (NVRO)
US64157F1030 - Common Stock
We assign a fundamental rating of 2 out of 10 to NVRO. NVRO was compared to 193 industry peers in the Health Care Equipment & Supplies industry. While NVRO seems to be doing ok healthwise, there are quite some concerns on its profitability. NVRO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NVRO has reported negative net income.
In the past year NVRO has reported a negative cash flow from operations.
In the past 5 years NVRO reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NVRO reported negative operating cash flow in multiple years.
1.2 Ratios
NVRO has a Return On Assets of -13.86%. This is comparable to the rest of the industry: NVRO outperforms 59.07% of its industry peers.
With a Return On Equity value of -29.65%, NVRO perfoms like the industry average, outperforming 58.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.86% | ||
| ROE | -29.65% | ||
| ROIC | N/A |
ROA(3y)-12.29%
ROA(5y)-13.9%
ROE(3y)-24.6%
ROE(5y)-28.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 68.92%, NVRO is doing good in the industry, outperforming 78.24% of the companies in the same industry.
In the last couple of years the Gross Margin of NVRO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NVRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVRO has more shares outstanding
The number of shares outstanding for NVRO has been increased compared to 5 years ago.
The debt/assets ratio for NVRO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.10, we must say that NVRO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.10, NVRO is in line with its industry, outperforming 46.63% of the companies in the same industry.
A Debt/Equity ratio of 0.77 indicates that NVRO is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.77, NVRO is not doing good in the industry: 73.58% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.1 |
ROIC/WACCN/A
WACC8.35%
2.3 Liquidity
NVRO has a Current Ratio of 7.38. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.38, NVRO belongs to the top of the industry, outperforming 82.90% of the companies in the same industry.
NVRO has a Quick Ratio of 5.57. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.57, NVRO belongs to the top of the industry, outperforming 80.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.57 |
3. Growth
3.1 Past
NVRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21600.00%.
The Revenue has been growing slightly by 3.85% in the past year.
Measured over the past years, NVRO shows a small growth in Revenue. The Revenue has been growing by 1.88% on average per year.
EPS 1Y (TTM)-21600%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40.82%
Revenue 1Y (TTM)3.85%
Revenue growth 3Y5.51%
Revenue growth 5Y1.88%
Revenue growth Q2Q5.78%
3.2 Future
Based on estimates for the next years, NVRO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.35% on average per year.
The Revenue is expected to grow by 6.12% on average over the next years.
EPS Next Y-5.3%
EPS Next 2Y6.02%
EPS Next 3Y8.95%
EPS Next 5Y12.35%
Revenue Next Year4.58%
Revenue Next 2Y5.29%
Revenue Next 3Y5.58%
Revenue Next 5Y6.12%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NVRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.02%
EPS Next 3Y8.95%
5. Dividend
5.1 Amount
NVRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEVRO CORP
NYSE:NVRO (5/17/2024, 7:17:02 PM)
After market: 11.4 0 (0%)11.4
+0.23 (+2.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap418.15M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.86% | ||
| ROE | -29.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.92% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.38 | ||
| Quick Ratio | 5.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21600%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.85%
Revenue growth 3Y5.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y